Prophylaxis in Vasculitis Cuts Risk for Non-PJP Infections
METHODOLOGY:
Researchers conducted an observational study that used a target trial emulation framework to examine the effect of prophylactic TMP-SMX on the incidence of serious infections in patients with ANCA-associated vasculitis.
They included 296 patients with new-onset or relapsing ANCA-associated vasculitis from four tertiary referral hospitals in South Korea who received either rituximab or cyclophosphamide as induction therapy between 2005 and 2023.
Of these, 240 patients received TMP-SMX prophylaxis (prophylaxis group; mean age, 63.7 years; 55.8% women) within 14 days of induction therapy, and 56 patients did not receive prophylaxis (control group; mean age, 61.5 years; 60.7% women) during the same period.
Physicians at each institution determined patient eligibility for prophylactic TMP-SMX, with dosage being either one single-strength tablet (TMP 80 mg and SMX 400 mg) daily or one double-strength tablet (TMP 160 mg and SMX 800 mg) every other day, adjusted for renal function.
The primary outcome was the incidence of serious infections requiring intravenous antimicrobial treatment, hospitalization, or extended hospital stay. Secondary outcomes included infection-related deaths and severe adverse drug reactions related to TMP-SMX.
TAKEAWAY:
Approximately 45.8% of patients discontinued the use of prophylactic TMP-SMX within the first 180 days. During 252.1 person-years of observation, 77 serious infections occurred in 65 patients, with an incidence rate of 30.5 per 100 person-years and a fatality rate of 18.5%. Most serious infections (85.7%) occurred within the first 180 days of observation (incidence rate ratio, 5.43; 95% CI, 2.87-10.28).
The prophylaxis group had a significantly lower 1-year incidence than the control group (hazard ratio [HR], 0.48; 95% CI, 0.32-0.72), particularly during the first 180 days (HR, 0.41; 95% CI, 0.22-0.76) but not thereafter (HR, 3.76; 95% CI, 0.46-29.43).
Infection-related mortality was also significantly lower in the prophylaxis group than in the control group (HR, 0.23; 95% CI, 0.10-0.53).
Over 127.4 person-years of TMP-SMX prophylaxis, 35 cases of adverse events occurred, eight of which were adverse drug reactions related to prophylactic TMP-SMX, and 27 patients discontinued TMP-SMX. Only one case of severe adverse drug reaction was noted, which was resolved after treatment discontinuation.
IN PRACTICE:
'Our results strongly suggest that prophylactic TMP-SMX provides additional benefits in patients with AAV [ANCA-associated vasculitis] beyond reducing the risk of PJP [ Pneumocystis jirovecii pneumonia],' the authors wrote.
SOURCE:
This study was led by Yun Kyu Kim, MD, Seoul National University College of Medicine, Seoul, Republic of Korea, and was published online on April 14, 2025, in Arthritis & Rheumatology .
LIMITATIONS:
Unmeasured confounders, such as compliance with prophylactic TMP-SMX, may have influenced the findings. The varied duration of TMP-SMX use in the prophylaxis group, with many patients discontinuing within 180 days, may have led to biased estimates. Additionally, the impact of TMP-SMX on COVID-19 incidence and related infectious complications could not be estimated for patients with an index date prior to 2018.
DISCLOSURES:
This study was supported by a grant from the National Research Foundation of Korea. One author reported receiving salary from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Two authors reported receiving grants and consulting fees from various pharmaceutical companies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Park Bom takes health break from 2NE1 group activities
8 Aug - Park Bom's camp recently announced that the singer will be taking a break from group activities with 2NE1 due to health issue. Sharing the news on 6 August, D-Nation Entertainment stated, "We are deeply saddened to deliver this news, especially as so many fans have shown their support for 2NE1's full-group activities." "Since medical staff recently advised that she needs sufficient rest and stability, we reached this unavoidable decision after careful discussion," they added. They also asked fans to give their support to Park Bom so that she can have good recovery. At the same time, the agency urged everybody to continue to show their love for Dara, CL and Minzy as they continue to perform without Park Bom. The 41-year-old singer was recently absent at the Waterbomb Busan 2025 Music Festival, where she was scheduled to perform on 26 July. She reunited with the rest of 2NE1 last year when they began performing to celebrate their 15th anniversary. (Photo Source: 2NE1 IG)
Yahoo
3 days ago
- Yahoo
Scientists stumble upon game-changing 'triple efficiency' in pursuit of powerful fuel: 'We plan to move forward'
Scientists stumble upon game-changing 'triple efficiency' in pursuit of powerful fuel: 'We plan to move forward' A team of researchers in South Korea may have just reshaped the future of green fuel. While developing a cleaner, more efficient way to produce ammonia, which is a compound that is widely used in fertilizers and looked at as a next-generation fuel, they stumbled upon a catalyst that delivers three times the output of the previous methods. The new catalyst, made of ruthenium (Ru) nanoparticles, was designed to increase efficiency in ammonia synthesis under milder conditions. According to a study reported by Tech Xplore, it achieved what researchers called "triple efficiency," which could slash pollution output and reduce the high energy costs that are associated with ammonia production. The increase in efficiency solves the issue of ammonia made at a global scale, mainly through the Haber-Bosch process, which requires an intense amount of heat and pressure. That method is responsible for nearly 1.3% of global planet-warming pollution like CO2, as per the International Energy Agency. The newly developed catalyst works at lower temperatures and pressures, which would cut down on both pollution and production costs. The study mentions that the structure of the catalyst is what makes the key difference. Researchers used a polyol-based method to expose more "B5-sites", a type of atomic configuration on the catalyst surface that boosts activity. The sites allow nitrogen and hydrogen to bond more easily and form ammonia and improve the overall efficiency. "We plan to move forward with performance verification through mass production of pellet-type catalysts and application in various ammonia cracking systems," study author Dr. Jeong Woo Han said in the Tech Xplore report. If scaled up, this could help industries reduce their carbon footprint while also enabling clean hydrogen transport. Since ammonia can store and move hydrogen, it's seen as a promising energy carrier in an economy that no longer relies on carbon pollution. While there is no set rollout timeline, the researchers believe their method can be adopted using existing infrastructure, which could help speed things up. Should the U.S. be investing more in battery production to catch up with China? Absolutely We're investing a good amount We should be investing less I have no idea Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
New York Times
4 days ago
- New York Times
Two Words: Plastics Treaty
What is plastic? The question isn't as silly as it sounds. The miraculous substances that suffuse our daily lives are not one material but many, differing wildly in look, feel and function, from the materials in Saran wrap to your kid's Legos to airplanes. Even two seemingly identical plastics are rarely the same because manufacturers add any number of additives, such as phthalates, flame retardants, perfluoroalkyl and polyfluoroalkyl substances, or PFAS, to imbue their products with additional flexibility, say, or heat resistance. By one estimate, there are at least 16,000 known chemical additives used by the plastics industry, of which at least 4,200 are known to be toxic. And because plastics inevitably break down into microplastics and then nanoplastics, eventually making their way into our lungs, guts, brains and even our unborn children, whatever is in our plastic is in us, too. This is a high-stakes moment for anyone invested in what plastics might be doing to our health. Beginning this week, representatives from more than 170 countries involved in a United Nations plastics treaty process are gathering in Geneva to try, for the sixth time, to negotiate the first global agreement to regulate the production, consumption and disposal of plastics. A previous meeting, held in South Korea in December, failed because of disagreements between countries pushing for an ambitious treaty and a group of fossil-fuel-producing nations, including Saudi Arabia, Russia, Iran and the United States. Among the causes for discord has been the question of plastics' impact on human health. This issue should concern all Americans, given the findings of the so-called Make America Healthy Again Commission, which highlighted the potential risks of microplastics, phthalates, PFAS and other plastics additives for children's health. Dozens of countries and an independent coalition of scientists want to ban plastics and chemical additives that are known or suspected to harm human health. But Saudi Arabia, the world's largest crude oil exporter, has argued that including language on the health impacts of plastics would distract from the treaty's core focus on pollution. The Trump administration has suggested that it would support only a treaty that protects American business interests. Exactly what, if anything, plastics are doing to our health remains hotly contested. But the signs aren't good. Researchers have linked microplastics consumption to an increased risk of cancer, respiratory disorders, bowel disease and male and female infertility. They are also known to trigger inflammation — a precondition for cancer — and possibly interfere with antibiotics. Researchers writing in the British medical journal The Lancet recently declared plastics 'a grave, growing and underrecognized danger to human and planetary health.' That might sound pretty damning, but proving whether microplastics are causing any specific disease is surprisingly hard. For one thing, much of the science on microplastics is relatively new and based on studies of animal or human cells in a lab. As Nicholas Chartres, a senior research fellow who studies microplastics at the University of Sydney Pharmacy School, told me, 'You can't ethically randomize people to be exposed to these chemicals.' Several long-term observational studies are ongoing, but conclusive results may be years away. Want all of The Times? Subscribe.
